Biotechnology Healthcare - November/December 2008 - (Page 24) PROCRIT ® (Epoetin alfa) FOR INJECTION DOSAGE AND ADMINISTRATION IMPORTANT: See BOXED WARNINGS and WARNINGS: Increased Mortality, Serious Cardiovascular and Thromboembolic Events. Prior to initiating treatment with PROCRIT® a hemoglobin should be obtained to establish that it is >10 to ≤ 13 g/dL. The recommended dose of PROCRIT® is 300 Units/kg/day subcutaneously for 10 days before surgery, on the day of surgery, and for 4 days after surgery. An alternate dose schedule is 600 Units/kg PROCRIT® subcutaneously in once weekly doses (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery. All patients should receive adequate iron supplementation. Iron supplementation should be initiated no later than the beginning of treatment with PROCRIT® and should continue throughout the course of therapy. Deep venous thrombosis prophylaxis should be strongly considered (see BOXED WARNINGS). PREPARATION AND ADMINISTRATION OF PROCRIT® 1. Do not shake. It is not necessary to shake PROCRIT®. Prolonged vigorous shaking may denature any glycoprotein, rendering it biologically inactive. 2. Protect the solution from light. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any vials exhibiting particulate matter or discoloration. 3. Using aseptic techniques, attach a sterile needle to a sterile syringe. Remove the flip top from the vial containing PROCRIT®, and wipe the septum with a disinfectant. Insert the needle into the vial, and withdraw into the syringe an appropriate volume of solution. 4. Single-dose: 1 mL vial contains no preservative. Use one dose per vial; do not re-enter the vial. Discard unused portions. Multidose: 1 mL and 2 mL vials contain preservative. Store at 2° to 8°C after initial entry and between doses. Discard 21 days after initial entry. 5. Do not dilute or administer in conjunction with other drug solutions. However, at the time of SC administration, preservative-free PROCRIT® from single-use vials may be admixed in a syringe with bacteriostatic 0.9% sodium chloride injection, USP, with benzyl alcohol 0.9% (bacteriostatic saline) at a 1:1 ratio using aseptic technique. The benzyl alcohol in the bacteriostatic saline acts as a local anesthetic which may ameliorate SC injection site discomfort. Admixing is not necessary when using the multidose vials of PROCRIT® containing benzyl alcohol. Try Our New Digital Edition The digital edition of BIOTECHNOLOGY HEALTHCARE is now available. On your computer screen, you see a complete copy of an issue as it would appear in print. With the digital edition, you can: • Click on the title of an article on the cover or in the table of contents, and go directly to that article. • Click on a URL anywhere in the magazine, and go directly to that Web page. • Search for any string of characters. • Make and save notes in the article you are reading. • Instantly e-mail a link to any article to an associate. • Get more information about advertised products by clicking on an ad. • Save the magazine file to your desktop for offline reading. • Print any or all pages of the magazine and any supplements mailed with it. How to Use the Digital Edition To navigate through the issue, use the control bar at the top of the screen. Turn the pages as you would do with the print edition. To access more help, click on the red question mark in the bar. Opens the Tools menu. View a list of all articles. Zoom in and out on the current page. Click the word “Zoom” to open the zoom configuration window. Switch to single-page view. Open the magnify window. Navigate to the previous or next page. Navigate to the cover or back page. Search the full text of the issue for a word or phrase. Print pages. Save an offline version to your computer. Save the direct link to an article to bookmark or email Biotechnology Healthcare Biosimilars: Will 2009 Be the Year? Page 27 THE IMPACT OF BIOLOGICS ON HEALTH, BUSINESS, AND BENEFITS NOVEMBER/DECEMBER 2008 The Official Journal of the Biologic Finance and Access Council www.biotechnologyhealthcare.com In Charge of Their Own Health Through VEBAs, unions are gaining control of health benefits. As companies transfer this responsibility, questions arise about access to high-tech therapies. Page 16 OLD IDEA, NEW TWIST Reinsurance For Biologics Page 31 Managing Hemophilia Patients Page 37 You can receive BIOTECHNOLOGY HEALTHCARE’S digital edition free by registering here: http://www.biotechnologyhealthcare.com/digital PREVIEW the digital edition: biotechnologyhealthcare.com/nxtbook SIGN UP NOW to receive an alert when each new issue is available: biotechnologyhealthcare.com/digital Manufactured by: Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 Distributed by: Ortho Biotech Products, L.P. Raritan, New Jersey 08869-0670 Revised 08/2008 © OBPLP 2000 10112802BC http://www.biotechnologyhealthcare.com http://www.biotechnologyhealthcare.com/nxtbook http://www.biotechnologyhealthcare.com/digital
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.